Vanda Pharmaceuticals (VNDA)

• Market cap: $304M
• 1 day: -2.13%
• 5 days: -4.72%
• 1 month: -17.75%
• 3 months: -28.37%
• 6 months: -35.09%
• Year to date: -38.79%
• 1 year: 7.91%
• 5 years: -71.74%
• 10 years: -55.7%
• Sector: Healthcare
• Industry: Biotechnology

About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Employees: 533